VERAXA Biotech (NASDAQ: VRXA) announced that shareholders overwhelmingly approved all proposals presented at its Extraordinary General Meeting, with more than 99.94% of votes cast in favor and 72.20% of the company's outstanding share capital represented. The approved measures include the introduction of conditional share capital for shareholder options and warrants, implementation of a capital band through Dec. 31, 2030 and an increase in the maximum size of the board of directors from five to seven members.
The company said the enhanced corporate and financing framework is intended to support its long-term growth strategy by providing greater flexibility for potential acquisitions, strategic collaborations, investment projects, capital markets activities and continued development of its BiTAC(R) technology platform and oncology pipeline. Management said the vote reflects strong shareholder support for VERAXA's strategy of advancing antibody-based cancer therapeutics while pursuing long-term value creation.
This approval is significant for VERAXA as it provides the company with the tools needed to execute on its strategic objectives. The introduction of conditional share capital allows for the issuance of shares upon exercise of options and warrants, which can be used to attract and retain talent, raise capital, or fund acquisitions. The capital band provides flexibility to increase share capital within a specified range without requiring further shareholder approval, streamlining future financing activities. The expanded board size enables the addition of directors with expertise relevant to the company's growth plans.
VERAXA focuses on discovering and developing next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. The company leverages a suite of transformative technologies and rigorous quality-by-design principles to advance its pipeline of ADCs and proprietary BiTAC formats into clinical development. Founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), VERAXA aims to build a premier engine for oncology therapeutics.
The shareholder vote underscores confidence in VERAXA's strategy amid a competitive oncology landscape. With the approved measures, the company is better positioned to pursue opportunities that could enhance its pipeline and create shareholder value. Investors can monitor updates on the company's progress through its newsroom.
Forward-looking statements in this article involve risks and uncertainties, including those detailed in the company's SEC filings. No undue reliance should be placed on these statements, and all parties undertake no duty to update them unless required by law.
